How an $84,000 drug got its price

Gilead Sciences executives were acutely aware in 2013 that their plan to charge an exorbitantly high price for a powerful new hepatitis C drug would spark public outrage, reports the Washington Post, but they pursued the profit-driven strategy anyway, according to a Senate Finance Committee investigation report released Tuesday.